A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

Study ID
NCT02060188

Study type
Interventional

Study phase
Phase 2

Study status
Active, not recruiting

Trial Acronym

CheckMate142

Trial Summary

The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in participants with colon cancer that has come back or has spread, and who have a specific biomarker in their tumors.

More informations

Trial Starting Date

Mar 12,2014

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

385